Publications by authors named "Gerhardt Attard"

100Publications

Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.

Urology 2020 Dec 26. Epub 2020 Dec 26.

Genitourinary Malignancies Research Center, Cleveland Clinic, Cleveland, OH; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article and Find Full Text PDF
December 2020

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".

Eur Urol Oncol 2020 08 24;3(4):412-419. Epub 2020 Jun 24.

Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, UK; FASTMAN Centre of Prostate Cancer Excellence, Manchester Cancer Research Centre, Manchester, UK; Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK; Department of Urology, The Salford NHS Foundation Trust, Manchester, UK. Electronic address:

View Article and Find Full Text PDF
August 2020

ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.

Bioinformatics 2020 05;36(9):2665-2674

Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento 38123, Italy.

View Article and Find Full Text PDF
May 2020

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.

Eur Urol 2019 12 23;76(6):719-728. Epub 2019 Aug 23.

The Christie and Royal Salford Hospitals, Manchester, UK; Genito Urinary Cancer Research Group and the FASTMAN Centre of Excellence, Division of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address:

View Article and Find Full Text PDF
December 2019

Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management.

Clin Chem 2019 01 11;65(1):100-107. Epub 2018 Dec 11.

University College London Cancer Institute, London, UK;

View Article and Find Full Text PDF
January 2019

Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.

Prostate Cancer Prostatic Dis 2019 05 9;22(2):195-205. Epub 2018 Nov 9.

Research Department of Oncology, University College London Cancer Institute, London, UK.

View Article and Find Full Text PDF
May 2019

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.

Sci Rep 2018 10 18;8(1):15442. Epub 2018 Oct 18.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Maroncelli 40, 47014, Meldola, Italy.

View Article and Find Full Text PDF
October 2018

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.

Int J Mol Sci 2018 Aug 29;19(9). Epub 2018 Aug 29.

Division of Radiotherapy & Imaging, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.

View Article and Find Full Text PDF
August 2018

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.

J Clin Oncol 2018 09 20;36(25):2639-2646. Epub 2018 Jul 20.

Gerhardt Attard, The Institute of Cancer Research and the Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Michael Borre, Aarhus University Hospital, Aarhus, Denmark; Howard Gurney, Macquarie University, Sydney, New South Wales, Australia; Yohann Loriot, Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U981, University of Paris Saclay, Villejuif, France; Corina Andresen-Daniil, Ranjith Kalleda, and Trinh Pham, Pfizer, New York, NY; and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article and Find Full Text PDF
September 2018

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.

Cancer Chemother Pharmacol 2018 09 5;82(3):457-468. Epub 2018 Jul 5.

Centre Hospitalier de l'Université de Montréal/CRCHUM, 900, rue St-Denis, porte R04-446, Montreal, Québec, H2X 0A9, Canada.

View Article and Find Full Text PDF
September 2018

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Nat Genet 2018 05 16;50(5):682-692. Epub 2018 Apr 16.

The Institute of Cancer Research, London, UK.

View Article and Find Full Text PDF
May 2018

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

N Engl J Med 2017 07 3;377(4):338-351. Epub 2017 Jun 3.

From the Institute of Cancer and Genomic Sciences, University of Birmingham (N.D.J.), and University Hospital Birmingham (A.Z.), Birmingham, the Institute of Cancer Research (J.S.B., D.P.D., G.A.), Medical Research Council Clinical Trials Unit at University College London (M.R. Spears, C.L.A., C.G., C.B., M.K.B.P., M.R. Sydes), King's College London and Guy's and St. Thomas' NHS Foundation Trust (S.C.), and Royal Marsden NHS Foundation Trust (C.C.P.), London, Salford Royal NHS Foundation Trust, Salford (N.W.C.), Cardiff University School of Medicine (M.D.M.) and Velindre Cancer Centre (J.F.L.), Cardiff, Gloucestershire Royal Hospital (A.W.S.R.) and Gloucestershire Hospitals NHS Foundation Trust (J.B.), Gloucester, University of Glasgow, Glasgow (R.J.J., J.M.R.), St. James's University Hospital, Leeds (W.R.C.), University Hospital of North-Midlands, Stoke-on-Trent (F.A.), Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter (S.A.), Rosemere Cancer Centre, Royal Preston Hospital, Preston (A.J.B.), Dorset Cancer Centre, Poole Hospital, Poole (S.B.), Royal Derby Hospital, Derby (P.C.), Weston Park Hospital, Sheffield (C.F.), Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth (J.G.), Musgrove Park Hospital, Taunton (E.G.), Hull and East Yorkshire Hospitals NHS Trust, Hull (M.H.), Mount Vernon Cancer Centre, Northwood (P.J.H.), Clatterbridge Cancer Centre, Wirral (Z.I.M.), Brighton and Sussex University Hospitals NHS Trust (F.M.) and Sussex Cancer Centre, Royal Sussex County Hospital (A.R.), Brighton, NHS Highland, Inverness (N.M.), Royal Surrey County Hospital, Guildford (J.M.-K.), Northern Ireland Cancer and Queens University, Belfast (J.O.), Lancashire Teaching Hospitals NHS Trust, Preston (O.P.), Churchill Hospital, Oxford (A.P.), Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury (N.N.S.), East Kent Hospitals NHS Trust, Canterbury (C.T.), Swansea University College of Medicine, Swansea (J. Wagstaff), and Christie NHS Foundation Trust, Manchester (J. Wylie) - all in the United Kingdom; and the Department of Medical Oncology, Kantonsspital St. Gallen, St. Gallen (S.G.), and University Hospital of Lausanne, Lausanne (D.R.B.) - both in Switzerland. Two of the authors (D.M., R.M.) were unaffiliated lay members of the STAMPEDE investigators.

View Article and Find Full Text PDF
July 2017

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

J Clin Oncol 2017 May 13;35(14):1530-1541. Epub 2017 Mar 13.

Malcolm D. Mason, Cardiff University School of Medicine, Velindre Hospital; Jim Barber, Velindre Cancer Centre, Cardiff; Noel W. Clarke, The Christie and Salford Royal NHS Foundation Trusts; John Logue, Christie Hospital, Manchester; Nicholas D. James, Institute of Cancer and Genomic Sciences; Emilio Porfiri, The Medical School, University of Birmingham; Nicholas D. James, Queen Elizabeth Hospital; Emilio Porfiri, University Hospitals Birmingham NHS Foundation Trust, Birmingham; David P. Dearnaley, Gerhardt Attard, and Christopher C. Parker, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust; Melissa R. Spears, Alastair W.S. Ritchie, Francesca Schiavone, David Matheson, Robin Millman, Clare Gilson, Mahesh K.B. Parmar, and Matthew R. Sydes, MRC Clinical Trials Unit at UCL, London; William Cross, Leeds Teaching Hospitals NHS Trust, Leeds; Rob J. Jones and J. Martin Russell, University of Glasgow; Rob J. Jones and Jan Wallace, Beatson West of Scotland Cancer Centre, Glasgow; Azman Ibrahim, The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral; Anna Lydon, Torbay District Hospital, Torquay; Ashok D. Nikapota, Sussex Cancer Centre, Brighton; Ashok D. Nikapota, Worthing Hospital, Worthing; Joe M. O'Sullivan, Centre for Cancer Research and Cell Biology, Queen's University, Belfast; Andrew Protheroe, Churchill Hospital, Oxford; Narayanan Nair Srihari, Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury; David Tsang, Southend Hospital, Southend-on-Sea; David Tsang, Basildon Hospital, Basildon; John Wagstaff, The South West Wales Cancer Institute; John Wagstaff, Swansea University College of Medicine, Swansea; Catherine Walmsley, Royal Preston Hospital, Preston, United Kingdom; George N. Thalmann, University Hospital; Estelle Cassoly, SAKK Coordinating Center, Berne; and Cyrill A. Rentsch, University Hospital Basel, Basel, Switzerland.

View Article and Find Full Text PDF
May 2017

Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.

Nat Rev Urol 2016 12 2;13(12):697-698. Epub 2016 Nov 2.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, Maryland 21231, USA.

View Article and Find Full Text PDF
December 2016

Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.

Am Soc Clin Oncol Educ Book 2016 ;35:131-41

From Weill Cornell Medicine, New York, NY, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY; The Institute of Cancer Research, London, United Kingdom, The Royal Marsden Hospital, London, United Kingdom.

View Article and Find Full Text PDF
January 2017

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.

Clin Genitourin Cancer 2016 12 5;14(6):485-493. Epub 2016 May 5.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address:

View Article and Find Full Text PDF
December 2016

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

Cancer Res 2016 05;76(9):2731-42

Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.

View Article and Find Full Text PDF
May 2016

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

N Engl J Med 2015 Oct;373(18):1697-708

From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.).

View Article and Find Full Text PDF
October 2015

Prostate cancer.

Lancet 2016 Jan 11;387(10013):70-82. Epub 2015 Jun 11.

Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address:

View Article and Find Full Text PDF
January 2016

Sequencing of agents in castration-resistant prostate cancer.

Lancet Oncol 2015 Jun 27;16(6):e279-92. Epub 2015 May 27.

Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article and Find Full Text PDF
June 2015

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

Nat Rev Urol 2015 Jun 26;12(6):312-3. Epub 2015 May 26.

The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK.

View Article and Find Full Text PDF
June 2015

The development of abiraterone acetate for castration-resistant prostate cancer.

Urol Oncol 2015 Jun;33(6):289-94

The Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article and Find Full Text PDF
June 2015

Integrative clinical genomics of advanced prostate cancer.

Cell 2015 May;161(5):1215-1228

Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article and Find Full Text PDF
May 2015

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

J Clin Oncol 2015 Apr 23;33(12):1348-55. Epub 2015 Mar 23.

Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article and Find Full Text PDF
April 2015

Targeting extra-gonadal androgens in castration-resistant prostate cancer.

J Steroid Biochem Mol Biol 2015 Jan 22;145:157-63. Epub 2014 Sep 22.

Institute of Cancer Research, Cancer Therapeutics, 15 Cotswold Rd, Sutton, Surrey SM25NG, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article and Find Full Text PDF
January 2015

Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.

Cancer 2014 Nov 3;120(21):3346-52. Epub 2014 Jul 3.

Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

View Article and Find Full Text PDF
November 2014

Evolution of androgen receptor targeted therapy for advanced prostate cancer.

Nat Rev Clin Oncol 2014 Jun 20;11(6):365-76. Epub 2014 May 20.

Division of Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK.

View Article and Find Full Text PDF
June 2014

Anti-androgen monotherapy for metastatic prostate cancer.

Authors:
Gerhardt Attard

Lancet Oncol 2014 May 14;15(6):543-4. Epub 2014 Apr 14.

The Royal Marsden NHS Trust and The Institute of Cancer Research, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK. Electronic address:

View Article and Find Full Text PDF
May 2014

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

J Natl Cancer Inst 2014 Apr 14;106(4):dju033. Epub 2014 Mar 14.

Affiliations of authors: Division of Radiotherapy and Imaging (TJG, NT, TJS, SPR), Cancer Research UK Cancer Therapeutics Unit (GB, MC, SM, GA, JdB, SAE, FED), and Molecular Pathology (FED), Institute of Cancer Research and Royal Marsden NHS Trust, Surrey, UK.

View Article and Find Full Text PDF
April 2014

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Eur Urol 2014 Sep 17;66(3):459-65. Epub 2013 Dec 17.

Prostate Cancer Targeted Therapy Group and Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK. Electronic address:

View Article and Find Full Text PDF
September 2014

A step toward functionally characterized prostate cancer molecular subtypes.

Nat Med 2013 Aug;19(8):966-7

Centre for Integrative Biology, University of Trento, Povo, Trento, Italy.

View Article and Find Full Text PDF
August 2013

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.

Cancer Treat Rev 2013 Dec 10;39(8):966-73. Epub 2013 Apr 10.

Endocrinology Unit, Azienda Ospedaliero Universitaria San Luigi, Orbassano, Italy.

View Article and Find Full Text PDF
December 2013

Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.

Curr Drug Targets 2013 Apr;14(4):408-19

Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, United Kingdom.

View Article and Find Full Text PDF
April 2013

Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.

Clin Cancer Res 2013 Jul 7;19(13):3353-9. Epub 2013 Mar 7.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article and Find Full Text PDF
July 2013

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Eur Urol 2013 Aug 4;64(2):300-6. Epub 2013 Jan 4.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

View Article and Find Full Text PDF
August 2013

Identifying prognostic signatures in the blood of ovarian cancer patients.

Gynecol Oncol 2013 Jan;128(1):1-2

The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK; Division of Clinical Studies, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. Electronic address:

View Article and Find Full Text PDF
January 2013

Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer.

Clin Chem 2013 Jan 30;59(1):75-84. Epub 2012 Nov 30.

Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.

View Article and Find Full Text PDF
January 2013

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

Mol Cancer Ther 2012 Jul 3;11(7):1609-17. Epub 2012 May 3.

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutic, The Institute of Cancer Research, Sutton,United Kingdom.

View Article and Find Full Text PDF
July 2012

Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

Nat Rev Urol 2012 Jan 17;9(2):63-4. Epub 2012 Jan 17.

Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article and Find Full Text PDF
January 2012

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Mol Cell Endocrinol 2012 Sep 1;360(1-2):68-75. Epub 2011 Oct 1.

Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF
September 2012

Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.

Clin Cancer Res 2011 Jun;17(12):3867-75

Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.

View Article and Find Full Text PDF
June 2011

Beyond hormone therapy for prostate cancer with PARP inhibitors.

Cancer Cell 2011 May;19(5):573-4

Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK.

View Article and Find Full Text PDF
May 2011

The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.

Eur Urol 2011 Aug 29;60(2):270-8. Epub 2011 Apr 29.

Veterans Affairs Medical Centre and the Baylor College of Medicine, Houston, TX, USA.

View Article and Find Full Text PDF
August 2011

The CT flare response of metastatic bone disease in prostate cancer.

Acta Radiol 2011 Jun 23;52(5):557-61. Epub 2011 Mar 23.

Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK.

View Article and Find Full Text PDF
June 2011

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.

Clin Cancer Res 2011 Apr 3;17(7):1649-57. Epub 2011 Mar 3.

Section of Medicine, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.

View Article and Find Full Text PDF
April 2011

Utilizing circulating tumor cells: challenges and pitfalls.

Curr Opin Genet Dev 2011 Feb 26;21(1):50-8. Epub 2010 Nov 26.

Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK.

View Article and Find Full Text PDF
February 2011

Steroid hormone receptors in prostate cancer: a hard habit to break?

Cancer Cell 2009 Dec;16(6):458-62

The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article and Find Full Text PDF
December 2009